Exeltis’ Slynd Receives the US FDA’s Approval for the Prevention of Pregnancy

 Exeltis’ Slynd Receives the US FDA’s Approval for the Prevention of Pregnancy

Exeltis’ Slynd Receives the US FDA’s Approval for the Prevention of Pregnancy

Shots:

  • The approval follows its clinical data assessing Slynd and has shown no instances of thromboembolic events experienced by some women taking COCs as well as the safety profile is supported with no black box warning like other contraceptives
  • The safety profile of Slynd was demonstrated by all patients including higher-risk populations like smokers, older women, and subjects with a Body Mass Index (BMI) >30
  • Slynd is an oral contraceptive progestin-only pill (POP) with estrogen-free administered as a 24 active with 4 inactive tablet dosing regimen and also allows a 24-hour missed pill window further providing improved bleeding profile and contraceptive efficacy for up to 24 hours. Exeltis plans to launch Slynd in early Fall 2019 

Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post